CLINICAL TRIALS PROFILE FOR VANCOMYCIN

505(b)(2) Clinical Trials for vancomycin

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Dosage	NCT01162733 ↗	Loading Vancomycin Doses in the Emergency Department	Completed	Christiana Care Health Services	N/A	2010-07-01	In 2008, our ED administered an average of 245 doses of vancomycin per month. Currently there is no consistency in the ED practice in regards to vancomycin dosing. In 2009, the IDSA put forth new recommendations for vancomycin dosing in order to achieve therapeutic levels more rapidly. It has been hypothesized that if therapeutic levels are reached more rapidly then patients will in turn have better clinical outcomes and that the development of resistant organisms will be decreased. Methicillin resistant Staphylococcus aureus (MRSA) has emerged as one of the most deadly pathogens that are currently plaguing our patient population. Vancomycin is one of only a few antibiotics that are effective for treating MRSA. It is imperative that the ED physicians consistently and correctly dose vancomycin in order to give the patients the best chance to fight infection while helping to prevent further resistance in this already highly resistant organism. It is believed this study will reveal that the new dosing recommendations by the IDSA will lead to the achievement of therapeutic levels more rapidly. This information will in turn help to convince ED physicians that a change in current clinical practice is warranted and ultimately lead to better clinically outcomes for the patients.
New Dosage	NCT01734694 ↗	Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients	Terminated	Henry Ford Health System	Phase 4	2011-10-01	For more than fifty years, vancomycin has been cited as a nephrotoxic agent. Reports of vancomycin induced kidney injury (a.k.a vancomycin induced nephrotoxicity or VIN), have waxed and waned throughout the years for various reasons. Recently, VIN has reemerged as a clinical concern. This may be due to various reasons, including new dosing recommendations as well as an increased prevalence of risk factors associated with vancomycin induced nephrotoxicity. This study aims to evaluate a strategy which attempts to reduce kidney damage from vancomycin use.
OTC	NCT04674839 ↗	The Impact of MS-20 on Gut Microbiota Composition in Adult Individuals	Completed	Microbio Co Ltd	N/A	2019-10-18	MicrSoy-20 (MS-20), a fermented soymilk product, has been approved as an Over the counter (OTC) drug in 2011. The therapeutic effect of MS-20 is to ameliorate symptoms such as fatigue and loss of appetite caused by cancer chemotherapy. Animal study revealed orally administration of MS-20 daily for 4 weeks altered the gut microbiota composition in mice. In addition, MS-20 could activate dendritic cell and improve immunotherapy response rate. Thus, it was hypothesis that MS-20 improves host immune activity thus ameliorate fatigue and increase weight is through alteration the gut microbiota composition. In this study, the ability of MS-20 in modulating gut microbiota and the subset of microbiome to be altered by MS-20 was investigated.

All Clinical Trials for vancomycin

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00003805 ↗	Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count	Completed	European Organisation for Research and Treatment of Cancer - EORTC	Phase 3	1997-11-01	RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
NCT00034294 ↗	A Study of GT160-246 Versus Vancomycin in Patients With Clostridium Difficile-Associated Diarrhea	Completed	Genzyme, a Sanofi Company	Phase 2	2002-02-01	Approximately 300 patients will be entered into this study taking place throughout the United States, Canada and the United Kingdom. This study aims to determine if an investigational drug is safe and effective for treating the symptoms of C. difficile-associated diarrhea and lowering the risk of repeat episodes of diarrhea. The investigational drug will be evaluated in comparison to current standard antibiotic treatment, so all patients will receive active medication. All study-related care is provided including doctor visits, physical exams, laboratory tests and study medication. Total length of participation is approximately 10 weeks.
NCT00035425 ↗	Treatment of Neutropenic Patients With Fever Who Are Suspected to Have A Gram Positive Infection	Completed	Pfizer	Phase 3	2001-11-01	This study will treat patients who have fever and neutropenia (after cancer chemotherapy) that is possibly due to a specific bacteria (gram positive bacteria).
NCT00035854 ↗	New Antibiotic to Treat Pediatric Patients With Infections Due to a Specific Bacteria (Vancomycin-Resistant Enterococcus)	Completed	Pfizer	Phase 3	2002-02-01	This study will treat pediatric patients who have infections that are due to a specific bacteria (Vancomycin-Resistant Enterococcus)

Clinical Trial Conditions for vancomycin

Condition Name

Condition Name for vancomycin
Intervention	Trials
Clostridium Difficile Infection	39
Surgical Site Infection	21
Infection	19
Clostridioides Difficile Infection	14

Condition MeSH

Condition MeSH for vancomycin
Intervention	Trials
Infections	163
Infection	141
Communicable Diseases	128
Clostridium Infections	85

Clinical Trial Locations for vancomycin

Trials by Country

Trials by Country for vancomycin
Location	Trials
Canada	102
Spain	43
United Kingdom	36
Brazil	34
Australia	34

Trials by US State

Trials by US State for vancomycin
Location	Trials
Texas	65
California	65
Ohio	53
Florida	51
New York	49

Clinical Trial Progress for vancomycin

Clinical Trial Phase

Clinical Trial Phase for vancomycin
Clinical Trial Phase	Trials
PHASE4	11
PHASE3	4
PHASE2	16

Clinical Trial Status

Clinical Trial Status for vancomycin
Clinical Trial Phase	Trials
Completed	194
Recruiting	94
Terminated	48

Clinical Trial Sponsors for vancomycin

Sponsor Name

Sponsor Name for vancomycin
Sponsor	Trials
Cubist Pharmaceuticals LLC	23
Pfizer	18
Forest Laboratories	11

Sponsor Type

Sponsor Type for vancomycin
Sponsor	Trials
Other	601
Industry	179
U.S. Fed	17

Vancomycin Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the current vancomycin clinical development footprint?

Vancomycin is an established, off-patent glycopeptide antibiotic with ongoing clinical and real-world evidence activity concentrated in (1) dose optimization, (2) therapeutic drug monitoring (TDM) and exposure targets, (3) special populations (pediatrics, renal impairment, obesity, critical care), and (4) comparative outcomes versus newer agents for selected indications. Formal “new drug” phase programs are limited relative to the scale of ongoing studies because the compound is long marketed and the core safety and efficacy package is already defined.

Primary clinical trial activity channels

• TDM optimization studies (AUC-guided dosing versus trough-based strategies)
• Pharmacokinetic and pharmacodynamic modeling in special populations
• Health outcomes studies using electronic health record or registry cohorts (dose/exposure targets, nephrotoxicity endpoints)
• Combination or protocol studies in difficult-to-treat infections (e.g., sepsis pathways, osteomyelitis regimens)

Implication for portfolio mapping For investors and R&D sponsors, vancomycin’s “development” has shifted from mechanism-to-clinic registration to operational optimization that can still generate clinically actionable guidance and may support label-adjacent updates (where regulators accept evidence quality and clinical relevance).

Which vancomycin clinical and labeling themes are driving recent trial work?

Across contemporary trial and practice guidelines, vancomycin programs repeatedly cluster around a small set of measurable targets:

Exposure targets and TDM method

• AUC-guided dosing is the dominant direction: trials and studies compare AUC estimation methods, sampling strategies, and dose adjustment protocols versus trough-based approaches.
• Clinical endpoints typically include:
  • treatment failure
  • microbiological clearance
  • nephrotoxicity (AKI definitions and timing)
  • time to appropriate therapy

Nephrotoxicity risk management

Clinical studies emphasize:

• dosing in augmented renal clearance
• dosing in obesity and renal impairment
• protocolized TDM frequency and algorithm-driven dose adjustments

Special populations

Programs frequently examine:

• pediatrics (age-dependent PK)
• critical care (variable PK and early dose adequacy)
• renal dysfunction (initial dosing and adjustment speed)

What does the vancomycin market look like today?

Vancomycin is a mature, high-volume hospital antibiotic used globally for gram-positive serious infections, especially where MRSA is involved or where susceptibility and stewardship protocols support its use.

Market structure

• Core use setting: hospitals and long-term acute-care providers
• Procurement dynamic: formulary inclusion and stewardship protocols
• Price pressure: high due to generics and multiple manufacturers
• Differentiation: shifts toward formulations with practical advantages (administration, stability, compatibility), and toward operational value (TDM support and dosing tools), rather than novel mechanism claims.

Competitive landscape

• Primary competitive pressure comes from:
  • newer MRSA-active agents used in selected settings (drug-class substitutes depending on local resistance and stewardship)
  • older comparator options where guidelines permit
• Vancomycin’s advantage stays strongest where:
  • susceptibility coverage is clear
  • stewardship targets discourage broader-spectrum alternatives
  • TDM infrastructure exists and dosing protocols are embedded

How do you size vancomycin’s addressable market by indication?

Vancomycin’s addressable clinical demand usually tracks serious gram-positive infections and MRSA pathways. The practical sizing method in hospital markets is often:

• volume of suspected or confirmed serious gram-positive infections
• MRSA prevalence and test positivity (where MRSA is tested)
• guideline-based empiric and targeted therapy use rates
• renal adjustment and TDM adoption affecting dosing continuity (not initial need, but dosing completion)

Common high-demand indication buckets

• skin and soft tissue infections (complicated)
• bloodstream infections (including catheter-related and MRSA bacteremia pathways)
• pneumonia and hospital-acquired infections where gram-positive targets are needed
• bone and joint infections (osteomyelitis and prosthetic complications)
• complicated intra-abdominal infections with resistant gram-positive components (where protocols include it)

What is the near-term commercial trajectory for vancomycin?

Given off-patent status, the market typically grows slowly in value and more in volume variability based on:

• infection incidence trends (including hospital acuity patterns)
• MRSA prevalence and susceptibility testing rates
• shifts in empiric guidelines and antimicrobial stewardship
• TDM adoption and protocol standardization
• competitive substitution by newer agents in certain geographies and formulary systems

Base case outlook (typical for an off-patent hospital antibiotic)

• Revenue growth: low single-digit to flat in many markets, driven by unit demand and minor pricing dynamics rather than product innovation.
• Volume sensitivity: higher variability with infection trends and formulary changes.
• Margin sensitivity: driven by generic pricing compression and tender dynamics.

What market projections are plausible for vancomycin through 2030?

Because vancomycin is widely genericized, projections should focus on the stable demand base and the offset between unit growth and pricing. The most actionable forward view is a range-based expectation framework rather than a “model of one path.”

Projection framework

• Scenario A (stable stewardship, steady MRSA burden):
  • modest volume growth with largely flat pricing
  • revenue roughly tracks infection incidence and hospital throughput
• Scenario B (shift toward newer anti-MRSA agents for selected indications):
  • volume erosion in targeted MRSA pathways
  • revenue stabilizes via substituting to other gram-positive indications
• Scenario C (stronger AUC/TDM protocols and protocol-driven adherence):
  • improved appropriate use and lower avoidable failures
  • supports sustained formulary position and reduces unnecessary discontinuations

What typically changes the slope

• MRSA epidemiology (prevalence and susceptibility)
• stewardship and guideline updates
• hospital adoption of AUC/TDM protocols
• competitive tendering and supply chain pricing

How should R&D investors evaluate clinical trial value in vancomycin today?

Vancomycin’s trial “value” is less about proving first-in-class mechanism and more about:

• reducing nephrotoxicity through protocolized dosing
• lowering treatment failure via improved exposure accuracy
• translating PK/TDM modeling into operational dosing that improves outcomes
• supporting label-adjacent guidance that hospitals will adopt in formularies and order sets

High-leverage evidence types

• randomized protocols comparing AUC-guided dosing versus trough-based dosing, with standardized AKI definitions
• pragmatic trials tied to order sets and TDM workflow
• pharmacometric analyses validated against observed concentrations
• comparative effectiveness in real-world cohorts using robust adjustment methods

What is the strategic implication for commercialization?

Commercial value in vancomycin is most often captured through:

• ensuring reliable supply and tender readiness
• maintaining formulary positioning through guideline alignment
• supporting clinical operations for TDM adoption
• maintaining product utility where hospital systems have standardized monitoring pathways

Key commercial moves typically do not require a “new vancomycin” molecule; they require operational and evidence alignment.

Where are the remaining clinical unmet needs?

Even with widespread use, unmet need persists where:

• exposure estimation is hardest (variable renal function, obesity, pediatrics)
• nephrotoxicity risk remains a barrier to optimal dosing
• time to target exposure can lag, especially early in severe infections
• protocol adherence varies across institutions

Key Takeaways

• Vancomycin clinical activity is concentrated in TDM and dosing optimization, with AUC-guided strategies as the central theme and nephrotoxicity reduction as a consistent endpoint.
• The market is mature and genericized, with revenue growth typically tied to volume and procurement dynamics rather than proprietary innovation.
• Competitive pressure comes from newer MRSA-active options in select formulary settings, but vancomycin retains demand where susceptibility coverage and stewardship favor it.
• The most actionable forward view is a scenario framework through 2030 that weighs infection incidence and MRSA epidemiology against substitution and pricing compression.
• Clinical trial value is highest when it improves dosing workflow outcomes (exposure accuracy, AKI reduction, treatment success) that hospitals can operationalize.

FAQs

1) Is vancomycin still running phase 3 trials for major new indications?

Most modern activity is protocol and dosing optimization rather than first-time registration-level phase work, reflecting vancomycin’s established status and off-patent market reality.

2) What endpoints matter most in recent vancomycin studies?

Studies most often track AUC or exposure attainment, treatment failure, and nephrotoxicity using standardized AKI definitions and timing.

3) Does AUC-guided dosing outperform trough-based dosing?

The prevailing direction of clinical guidance and comparative study designs is toward AUC-guided dosing because it improves exposure targeting and reduces nephrotoxicity risk relative to less precise approaches.

4) What drives vancomycin demand commercially?

Hospital infection burden and MRSA-related treatment pathways drive baseline demand, while tender price and formulary substitution determine revenue realization.

5) What is the biggest commercial risk for vancomycin through 2030?

Formulary substitution to newer MRSA-active agents in specific indications and geographies, combined with generic pricing pressure, tends to cap value growth.

---

References

[1] Rybak MJ, Le J, Lodise TP. Therapeutic monitoring of vancomycin: A revised approach based on AUC-guided dosing. Clin Infect Dis.
[2] EUCAST. Vancomycin dosing and PK/PD guidance resources (updated periodic guidance). EUCAST Technical Documents.
[3] IDSA/ASHP/SIDP. Vancomycin therapeutic monitoring consensus guidance (AUC targets and monitoring strategy). Infectious Diseases Society of America / American Society of Health-System Pharmacists / Society of Infectious Diseases Pharmacists.

Note: Only cited sources are included.